Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Boosted by Russell Investments Group Ltd.

Russell Investments Group Ltd. raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 137,208 shares of the biopharmaceutical company’s stock after buying an additional 7,944 shares during the period. Russell Investments Group Ltd.’s holdings in Regeneron Pharmaceuticals were worth $97,690,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Willner & Heller LLC increased its holdings in shares of Regeneron Pharmaceuticals by 3.9% in the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock valued at $284,000 after purchasing an additional 15 shares during the period. OLD Second National Bank of Aurora lifted its holdings in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock worth $2,025,000 after purchasing an additional 15 shares during the last quarter. Rakuten Securities Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 15 shares during the period. TD Private Client Wealth LLC increased its stake in shares of Regeneron Pharmaceuticals by 9.6% in the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 15 shares during the period. Finally, Manchester Capital Management LLC increased its position in Regeneron Pharmaceuticals by 12.6% in the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 18 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of research reports. JPMorgan Chase & Co. lowered their price objective on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating on the stock in a research report on Monday, March 31st. Sanford C. Bernstein decreased their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Citigroup dropped their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Finally, BMO Capital Markets reduced their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $966.88.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $573.45 on Friday. The company has a market capitalization of $62.69 billion, a price-to-earnings ratio of 14.98, a PEG ratio of 2.34 and a beta of 0.44. The business has a 50 day moving average of $676.70 and a 200 day moving average of $779.13. Regeneron Pharmaceuticals, Inc. has a 1-year low of $572.00 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the prior year, the firm posted $11.86 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.61%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.